CA2886747C - Treating vascular disease and complications thereof - Google Patents
Treating vascular disease and complications thereof Download PDFInfo
- Publication number
- CA2886747C CA2886747C CA2886747A CA2886747A CA2886747C CA 2886747 C CA2886747 C CA 2886747C CA 2886747 A CA2886747 A CA 2886747A CA 2886747 A CA2886747 A CA 2886747A CA 2886747 C CA2886747 C CA 2886747C
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- human subject
- pharmaceutical composition
- administration
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Surgery (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261709754P | 2012-10-04 | 2012-10-04 | |
| US61/709,754 | 2012-10-04 | ||
| PCT/US2013/062903 WO2014055544A1 (en) | 2012-10-04 | 2013-10-01 | Treating vascular disease and complications thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2886747A1 CA2886747A1 (en) | 2014-04-10 |
| CA2886747C true CA2886747C (en) | 2023-12-05 |
Family
ID=50432830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2886747A Active CA2886747C (en) | 2012-10-04 | 2013-10-01 | Treating vascular disease and complications thereof |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20140099321A1 (enExample) |
| EP (3) | EP2904010A4 (enExample) |
| JP (1) | JP6460993B2 (enExample) |
| KR (2) | KR102429919B1 (enExample) |
| CN (2) | CN104684929A (enExample) |
| AU (1) | AU2013327501B2 (enExample) |
| CA (1) | CA2886747C (enExample) |
| HK (1) | HK1211960A1 (enExample) |
| IL (1) | IL237765B (enExample) |
| MX (1) | MX376241B (enExample) |
| RU (1) | RU2671955C2 (enExample) |
| WO (1) | WO2014055544A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102946904A (zh) | 2010-06-18 | 2013-02-27 | 埃克斯生物科技公司 | 关节炎治疗 |
| PH12013500316A1 (en) | 2010-08-23 | 2016-09-02 | Janssen Biotech Inc | Treatment for neoplastic diseases |
| US9724409B2 (en) | 2011-04-01 | 2017-08-08 | Xbiotech, Inc. | Treatment of inflammatory skin disease |
| PT2750709T (pt) | 2011-09-23 | 2018-11-22 | Xbiotech Inc | Tratamento da caquexia |
| US9545441B2 (en) | 2012-09-18 | 2017-01-17 | Xbiotech, Inc. | Treatment of diabetes |
| JP7145162B2 (ja) | 2017-02-16 | 2022-09-30 | ヤンセン バイオテク，インコーポレイテッド | 化膿性汗腺炎の処置 |
| AU2020267329B2 (en) * | 2019-05-03 | 2026-03-26 | University Of Zurich | Treatment of brain ischemia-reperfusion injury |
| CA3095675A1 (en) | 2020-10-07 | 2022-04-07 | Xbiotech Inc. | True human antibody specific for interleukin 1 alpha (il-1a) |
| CA3095676A1 (en) | 2020-10-07 | 2022-04-07 | Xbiotech Inc. | True human antibody specific for interleukin 1 alpha (il-1a) |
| CA3095740A1 (en) | 2020-10-07 | 2022-04-07 | Xbiotech Inc. | True human antibody specific for interleukin alpha (il-1a) |
| CA3095679A1 (en) | 2020-10-07 | 2022-04-07 | Xbiotech Inc. | True human antibody specific for interleuken 1 alpha (il-1a) |
| KR102652849B1 (ko) | 2022-03-14 | 2024-04-01 | 한국화학연구원 | 극성 아라미드 나노섬유로 제조한 하이드로겔 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH652145A5 (de) | 1982-01-22 | 1985-10-31 | Sandoz Ag | Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen. |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| RU2235541C2 (ru) * | 1994-10-04 | 2004-09-10 | Эмори Юниверсити | Лечение атеросклероза и других сердечно-сосудистых и воспалительных заболеваний |
| WO2000071753A2 (en) * | 1999-05-24 | 2000-11-30 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for restenosis |
| EP1471931A4 (en) * | 2001-08-24 | 2006-06-14 | Maine Medical Ct Res Inst | NON-TRADITIONAL EXPORT OF COPPER-DEPENDENT PRO-INFLAMMATORY CYTOKINES AND METHODS, COMPOSITIONS, AND KITS THEREOF |
| US20040224893A1 (en) * | 2003-05-06 | 2004-11-11 | Li-Hsien Wang | Methods of using IL-1 antagonists to treat neointimal hyperplasia |
| HUE029003T2 (en) * | 2008-05-30 | 2017-01-30 | Xbiotech Inc | IL-1 alpha antibodies |
| SG2014014534A (en) * | 2009-05-29 | 2014-07-30 | Xoma Technology Ltd | CARDIOVASCULAR RELATED USES OF IL-1ß ANTIBODIES AND BINDING FRAGMENTS THEREOF |
| JP5812669B2 (ja) | 2011-04-27 | 2015-11-17 | キヤノン株式会社 | 画像処理装置および画像処理方法およびコンピュータプログラム。 |
-
2013
- 2013-10-01 HK HK15112832.0A patent/HK1211960A1/xx unknown
- 2013-10-01 AU AU2013327501A patent/AU2013327501B2/en active Active
- 2013-10-01 KR KR1020217027089A patent/KR102429919B1/ko active Active
- 2013-10-01 JP JP2015535742A patent/JP6460993B2/ja active Active
- 2013-10-01 WO PCT/US2013/062903 patent/WO2014055544A1/en not_active Ceased
- 2013-10-01 CA CA2886747A patent/CA2886747C/en active Active
- 2013-10-01 EP EP13843772.8A patent/EP2904010A4/en not_active Ceased
- 2013-10-01 KR KR1020157009716A patent/KR102296017B1/ko active Active
- 2013-10-01 CN CN201380051667.8A patent/CN104684929A/zh active Pending
- 2013-10-01 EP EP18215704.0A patent/EP3524621A1/en not_active Ceased
- 2013-10-01 RU RU2015110635A patent/RU2671955C2/ru active
- 2013-10-01 MX MX2015004286A patent/MX376241B/es active IP Right Grant
- 2013-10-01 CN CN202110285555.5A patent/CN113018431A/zh active Pending
- 2013-10-01 EP EP25187641.3A patent/EP4628162A3/en active Pending
- 2013-10-02 US US14/044,418 patent/US20140099321A1/en not_active Abandoned
-
2015
- 2015-03-16 IL IL237765A patent/IL237765B/en active IP Right Grant
-
2017
- 2017-11-01 US US15/800,407 patent/US20180057585A1/en not_active Abandoned
-
2021
- 2021-09-10 US US17/471,702 patent/US20210403548A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013327501B2 (en) | 2018-08-09 |
| CN113018431A (zh) | 2021-06-25 |
| EP2904010A1 (en) | 2015-08-12 |
| AU2013327501A1 (en) | 2015-04-02 |
| WO2014055544A1 (en) | 2014-04-10 |
| EP3524621A1 (en) | 2019-08-14 |
| MX2015004286A (es) | 2015-08-06 |
| MX376241B (es) | 2025-03-06 |
| US20180057585A1 (en) | 2018-03-01 |
| JP2015531397A (ja) | 2015-11-02 |
| EP4628162A3 (en) | 2025-12-03 |
| KR20150063076A (ko) | 2015-06-08 |
| JP6460993B2 (ja) | 2019-01-30 |
| KR102296017B1 (ko) | 2021-09-01 |
| US20210403548A1 (en) | 2021-12-30 |
| IL237765B (en) | 2019-06-30 |
| US20140099321A1 (en) | 2014-04-10 |
| CA2886747A1 (en) | 2014-04-10 |
| EP2904010A4 (en) | 2016-06-01 |
| EP4628162A2 (en) | 2025-10-08 |
| RU2671955C2 (ru) | 2018-11-08 |
| CN104684929A (zh) | 2015-06-03 |
| KR102429919B1 (ko) | 2022-08-05 |
| IL237765A0 (en) | 2015-05-31 |
| RU2015110635A (ru) | 2016-11-27 |
| HK1211960A1 (en) | 2016-06-03 |
| KR20210108496A (ko) | 2021-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2013327501B2 (en) | Treating vascular disease and complications thereof | |
| US12116405B2 (en) | Arthritis treatment | |
| US20250236669A1 (en) | Antibodies That Bind Human Cannabinoid 1 (CB1) Receptor | |
| CA2849710C (en) | Cachexia treatment | |
| CN104398471A (zh) | 稳定的抗体组合物和用于稳定其的方法 | |
| WO2012125680A1 (en) | Methods of treating vasculitis using an il-17 binding molecule | |
| AU2012236106A1 (en) | Treatment for dermatological pathologies | |
| AU2013327498A1 (en) | Treatment of psychiatric conditions | |
| US20130195877A1 (en) | Treatment of cachexia by targeting interleukin-1 beta | |
| HK40130815A (en) | Treating vascular disease and complications thereof | |
| HK40012735A (en) | Treating vascular disease and complications thereof | |
| HK40053657A (en) | Treating vascular disease and complications thereof | |
| TW202434625A (zh) | Lag-3及pd-1/lag-3抗體 | |
| KR20260006622A (ko) | 다제내성 세균 감염의 치료 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20180928 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD Year of fee payment: 12 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250926 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250926 |